For immediate release |
22 November 2011 |
Futura Medical plc
("Futura" or "the Company")
Block Listing Update
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that in the six months from the block admission application to AIM on 25 May 2011 for a total of 2,335,000 ordinary shares of 0.2p each in the Company the following changes have taken place:
Futura Medical plc Option Plan |
No of Shares in Block Admission |
Options Exercised in Period |
Block Listing Carried Forward |
|
|
|
|
Unapproved Share Option Scheme |
814,424 |
(130,269) |
684,155 |
EMI Share Option Scheme |
1,520,576 |
(49,731) |
1,470,845 |
|
2,335,000 |
(180,000) |
2,155,000 |
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive |
Tel: +44 (0) 1483 685 670 |
|
|
mail to: james.barder@futuramedical.com |
|
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny |
Tel:+44 (0)20 7776 1200 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan |
|
Mark Court / Jessica Fontaine |
Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.